-
1
-
-
0029021935
-
Incidence of second cancers in patients treated for Hodgkin's disease
-
Boivin JF, Hutchison GB, Zauber AG et al. Incidence of second cancers in patients treated for Hodgkin's disease. J Natl Cancer Inst 1995; 87: 732-41.
-
(1995)
J Natl Cancer Inst
, vol.87
, pp. 732-741
-
-
Boivin, J.F.1
Hutchison, G.B.2
Zauber, A.G.3
-
2
-
-
0033952110
-
Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood
-
van Leeuwen FE, Klokman WJ, Veer MB et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 2000; 18: 487-97.
-
(2000)
J Clin Oncol
, vol.18
, pp. 487-497
-
-
van Leeuwen, F.E.1
Klokman, W.J.2
Veer, M.B.3
-
3
-
-
0037089650
-
Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger
-
Ng AK, Bernardo MP, Weller E et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 2002; 20: 2101-8.
-
(2002)
J Clin Oncol
, vol.20
, pp. 2101-2108
-
-
Ng, A.K.1
Bernardo, M.P.2
Weller, E.3
-
4
-
-
33845354279
-
Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials
-
Franklin J, Pluetschow A, Paus M et al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Ann Oncol 2006; 17: 1749-60.
-
(2006)
Ann Oncol
, vol.17
, pp. 1749-1760
-
-
Franklin, J.1
Pluetschow, A.2
Paus, M.3
-
5
-
-
33745982566
-
Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials
-
Noordijk EM, Carde P, Dupouy N et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 2006; 24: 3128-35.
-
(2006)
J Clin Oncol
, vol.24
, pp. 3128-3135
-
-
Noordijk, E.M.1
Carde, P.2
Dupouy, N.3
-
6
-
-
34548186696
-
Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial
-
Engert A, Franklin J, Eich HT et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol 2007; 25: 3495-502.
-
(2007)
J Clin Oncol
, vol.25
, pp. 3495-3502
-
-
Engert, A.1
Franklin, J.2
Eich, H.T.3
-
7
-
-
9444292843
-
Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease
-
Straus DJ, Portlock CS, Qin J et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 2004; 104: 3483-9.
-
(2004)
Blood
, vol.104
, pp. 3483-3489
-
-
Straus, D.J.1
Portlock, C.S.2
Qin, J.3
-
8
-
-
10944270230
-
Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study
-
Rueda Domínguez A, Márquez A, Gumá J et al. Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study. Ann Oncol 2004; 15: 1798-804.
-
(2004)
Ann Oncol
, vol.15
, pp. 1798-1804
-
-
Rueda Domínguez, A.1
Márquez, A.2
Gumá, J.3
-
9
-
-
33645998113
-
The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease
-
Gallamini A, Rigacci L, Merli F et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006; 91: 475-81.
-
(2006)
Haematologica
, vol.91
, pp. 475-481
-
-
Gallamini, A.1
Rigacci, L.2
Merli, F.3
-
10
-
-
30144432586
-
FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
-
Hutchings M, Loft A, Hansen M et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107: 52-9.
-
(2006)
Blood
, vol.107
, pp. 52-59
-
-
Hutchings, M.1
Loft, A.2
Hansen, M.3
-
11
-
-
34548486030
-
Early interim 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study
-
Gallamini A, Hutchings M, Rigacci L et al. Early interim 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007; 25: 3746-52.
-
(2007)
J Clin Oncol
, vol.25
, pp. 3746-3752
-
-
Gallamini, A.1
Hutchings, M.2
Rigacci, L.3
-
12
-
-
0036124658
-
Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma
-
Wirth A, Seymour JF, Hicks RJ et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med 2002; 112: 262-8.
-
(2002)
Am J Med
, vol.112
, pp. 262-268
-
-
Wirth, A.1
Seymour, J.F.2
Hicks, R.J.3
-
13
-
-
9444279658
-
Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease
-
Munker R, Glass J, Griffeth LK et al. Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease. Ann Oncol 2004; 15: 1699-704.
-
(2004)
Ann Oncol
, vol.15
, pp. 1699-1704
-
-
Munker, R.1
Glass, J.2
Griffeth, L.K.3
-
14
-
-
0036938607
-
Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease
-
Weihrauch MR, Re D, Bischoff S et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Ann Hematol 2002; 81: 20-5.
-
(2002)
Ann Hematol
, vol.81
, pp. 20-25
-
-
Weihrauch, M.R.1
Re, D.2
Bischoff, S.3
-
15
-
-
25444437438
-
Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma
-
Hutchings M, Mikhaeel NG, Fields PA et al. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005; 16: 1160-8.
-
(2005)
Ann Oncol
, vol.16
, pp. 1160-1168
-
-
Hutchings, M.1
Mikhaeel, N.G.2
Fields, P.A.3
-
16
-
-
84861469135
-
Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement
-
Song MK, Chung JS, Shin HJ et al. Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement. Ann Hematol 2012; 91: 697-703.
-
(2012)
Ann Hematol
, vol.91
, pp. 697-703
-
-
Song, M.K.1
Chung, J.S.2
Shin, H.J.3
-
17
-
-
84859741903
-
Prognostic value of metabolic tumor volume on PET/CT in primary gastrointestinal diffuse large B cell lymphoma
-
Song MK, Chung JS, Shin HJ et al. Prognostic value of metabolic tumor volume on PET/CT in primary gastrointestinal diffuse large B cell lymphoma. Cancer Sci 2012; 103: 477-82.
-
(2012)
Cancer Sci
, vol.103
, pp. 477-482
-
-
Song, M.K.1
Chung, J.S.2
Shin, H.J.3
-
18
-
-
84870907232
-
Clinical value of metabolic tumor volume by PET/CT in extranodal natural killer/T cell lymphoma
-
Song MK, Chung JS, Shin HJ et al. Clinical value of metabolic tumor volume by PET/CT in extranodal natural killer/T cell lymphoma. Leuk Res 2013; 37: 58-63.
-
(2013)
Leuk Res
, vol.37
, pp. 58-63
-
-
Song, M.K.1
Chung, J.S.2
Shin, H.J.3
-
19
-
-
84887588744
-
Prognostic value of Waldeyer's ring involvement of diffuse large B-cell lymphoma treated with R-CHOP
-
Oh MY, Chung JS, Song MK et al. Prognostic value of Waldeyer's ring involvement of diffuse large B-cell lymphoma treated with R-CHOP. Int J Hematol 2013; 97: 397-402.
-
(2013)
Int J Hematol
, vol.97
, pp. 397-402
-
-
Oh, M.Y.1
Chung, J.S.2
Song, M.K.3
-
20
-
-
0141939066
-
Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma
-
Engert A, Schiller P, Josting A et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma. J Clin Oncol 2003; 19: 3601-8.
-
(2003)
J Clin Oncol
, vol.19
, pp. 3601-3608
-
-
Engert, A.1
Schiller, P.2
Josting, A.3
-
21
-
-
0024422603
-
Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: cotswolds meeting
-
Lister TA, Crowther D, Sutcliffe SB et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: cotswolds meeting. J Clin Oncol 1989; 7: 1630-6.
-
(1989)
J Clin Oncol
, vol.7
, pp. 1630-1636
-
-
Lister, T.A.1
Crowther, D.2
Sutcliffe, S.B.3
-
23
-
-
72949107608
-
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0
-
Boellaard R, O'Doherty MJ, Weber WA et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010; 37: 181-200.
-
(2010)
Eur J Nucl Med Mol Imaging
, vol.37
, pp. 181-200
-
-
Boellaard, R.1
O'Doherty, M.J.2
Weber, W.A.3
-
24
-
-
21044445135
-
The EORTC strategy in the treatment of Hodgkin's lymphoma
-
Eghbali H, Raemaekers J, Carde P. The EORTC strategy in the treatment of Hodgkin's lymphoma. Eur J Haematol Suppl 2005; 66: 135-40.
-
(2005)
Eur J Haematol Suppl
, vol.66
, pp. 135-140
-
-
Eghbali, H.1
Raemaekers, J.2
Carde, P.3
-
25
-
-
84861813756
-
National Comprehensive Cancer Network. Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines
-
Hoppe RT, Advani RH, Ai WZ et al. National Comprehensive Cancer Network. Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012; 10: 589-97.
-
(2012)
J Natl Compr Canc Netw
, vol.10
, pp. 589-597
-
-
Hoppe, R.T.1
Advani, R.H.2
Ai, W.Z.3
-
26
-
-
0037905550
-
Hodgkin's disease-clinical trials and travails
-
DeVita VT Jr. Hodgkin's disease-clinical trials and travails. N Engl J Med 2003; 348: 2375-6.
-
(2003)
N Engl J Med
, vol.348
, pp. 2375-2376
-
-
DeVita Jr., V.T.1
-
27
-
-
0042308850
-
Radiation therapy in the treatment of Hodgkin's disease-do you see what I see?
-
Longo DL. Radiation therapy in the treatment of Hodgkin's disease-do you see what I see? J Natl Cancer Inst 2003; 95: 928-9.
-
(2003)
J Natl Cancer Inst
, vol.95
, pp. 928-929
-
-
Longo, D.L.1
-
28
-
-
26944442771
-
Radiation therapy in Hodgkin disease: why risk a Pyrrhic victory?
-
Longo DL. Radiation therapy in Hodgkin disease: why risk a Pyrrhic victory? J Natl Cancer Inst 2005; 97: 1394-5.
-
(2005)
J Natl Cancer Inst
, vol.97
, pp. 1394-1395
-
-
Longo, D.L.1
-
29
-
-
23044438039
-
Chemotherapy alone for early Hodgkin's lymphoma: an emerging option
-
Canellos GP. Chemotherapy alone for early Hodgkin's lymphoma: an emerging option. J Clin Oncol 2005; 23: 4574-6.
-
(2005)
J Clin Oncol
, vol.23
, pp. 4574-4576
-
-
Canellos, G.P.1
-
30
-
-
0035281969
-
Image-aided estimate of tumor burden in Hodgkin's disease: evidence of its primary prognostic importance
-
Gobbi PG, Ghirardelli ML, Solcia M et al. Image-aided estimate of tumor burden in Hodgkin's disease: evidence of its primary prognostic importance. J Clin Oncol 2001; 19: 1388-94.
-
(2001)
J Clin Oncol
, vol.19
, pp. 1388-1394
-
-
Gobbi, P.G.1
Ghirardelli, M.L.2
Solcia, M.3
-
31
-
-
4744376311
-
The clinical value of tumor burden at diagnosis in Hodgkin lymphoma
-
Gobbi PG, Broglia C, Di Giulio G et al. The clinical value of tumor burden at diagnosis in Hodgkin lymphoma. Cancer 2004; 101: 1824-34.
-
(2004)
Cancer
, vol.101
, pp. 1824-1834
-
-
Gobbi, P.G.1
Broglia, C.2
Di Giulio, G.3
-
32
-
-
0033566341
-
Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging
-
Jerusalem G, Beguin Y, Fassotte MF et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999; 94: 429-33.
-
(1999)
Blood
, vol.94
, pp. 429-433
-
-
Jerusalem, G.1
Beguin, Y.2
Fassotte, M.F.3
-
33
-
-
0032587391
-
Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma
-
Jerusalem G, Warland V, Najjar F et al. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Commun 1999; 20: 13-20.
-
(1999)
Nucl Med Commun
, vol.20
, pp. 13-20
-
-
Jerusalem, G.1
Warland, V.2
Najjar, F.3
-
34
-
-
0031869324
-
Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography
-
Stumpe KD, Urbinelli M, Steinert HC et al. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998; 25: 721-8.
-
(1998)
Eur J Nucl Med
, vol.25
, pp. 721-728
-
-
Stumpe, K.D.1
Urbinelli, M.2
Steinert, H.C.3
-
35
-
-
34748865484
-
The International Harmonization Project for response criteria in lymphoma clinical trials
-
Cheson BD. The International Harmonization Project for response criteria in lymphoma clinical trials. Hematol Oncol Clin North Am 2007; 21: 841-54.
-
(2007)
Hematol Oncol Clin North Am
, vol.21
, pp. 841-854
-
-
Cheson, B.D.1
|